Drug Trial Radar · NCT04202965
PTG-300 in Subjects With Hereditary Hemochromatosis
Last checked: Nov 20, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Mar 19, 2020
Primary completion
Oct 6, 2021
Study completion Feb 15, 2022
Sponsor
- Lead sponsor
- Protagonist Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.
Conditions
- Hereditary Hemochromatosis
Interventions
PTG-300Drug
Active treatment with PTG-300 injected subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect of PTG-300 on Transferrin SaturationTime frame: Week 24 (or End of Treatment if treated for less than 24 weeks)
- Effect of PTG-300 on Serum IronTime frame: Week 24 (or End of Treatment if treated for less than 24 weeks)
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Protagonist Investigational Site
Fayetteville, Georgia
Protagonist Investigational Site
Bethesda, Maryland
Protagonist Investigational Site
Charlotte, North Carolina
Protagonist Investigational Site
Conroe, Texas
Protagonist Investigational Site
Dallas, Texas
Protagonist Investigational Site
Houston, Texas
Protagonist Investigational Site
Houston, Texas
Protagonist Investigational Site
Richmond, Virginia
Protagonist Investigational Site
Seattle, Washington
Protagonist Investigational Site
Halifax, Nova Scotia, Canada
Protagonist Investigational Site
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.